| Symbol | ZVRA |
|---|---|
| Name | ZEVRA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1180 CELEBRATION BOULEVARD,SUITE 103, CELEBRATION, Florida, 34747, United States |
| Telephone | +1 321 939-3416 |
| Fax | — |
| — | |
| Website | https://www.zevra.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001434647 |
| Description | Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Companys lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Companys prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Additional info from NASDAQ: |
Thompson Rahsaan 🔴 sold 42.7K shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.13 Transaction Date: Aug 14, 2026 | Filing ID: 000073
Read more📋 RAHSAAN THOMPSON (Officer) plans to sell 43K shares of ZEVRA THERAPEUTICS INC (at $11.18 each, total $477K) Filed: Aug 14, 2026 | ID: 008134
Read moreNew Form SCHEDULE 13G/A - ZEVRA THERAPEUTICS, INC. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005266 <b>Size:</b> 9 KB
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Read moreDirector Watton Corey Michael 🟡 adjusted position in 12.3K shares (1 derivative) of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.25 Transaction Date: Aug 10, 2026 | Filing ID: 000070
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Read moreZevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Read moreZevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Read moreNew Form SCHEDULE 13G - ZEVRA THERAPEUTICS, INC. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001518 <b>Size:</b> 7 KB
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07125066 | An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2… | Phase1 | Combined D,L-2-hydroxyglutaric Aciduria | Enrolling_By_Invitation | 2025-07-30 | 2027-12-01 | ClinicalTrials.gov |
| NCT06773026 | Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Ad… | Phase2 | Medium-chain Acyl-CoA Dehydrogenase Deficiency | Recruiting | 2025-06-30 | 2027-07-01 | ClinicalTrials.gov |
| NCT05668754 | Study of SDX in Patients With Idiopathic Hypersomnia (IH) | Phase2 | Idiopathic Hypersomnia | Completed | 2022-12-28 | 2024-03-21 | ClinicalTrials.gov |
| NCT03460652 | KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD | Phase3 | ADHD | Completed | 2018-03-13 | 2019-07-09 | ClinicalTrials.gov |
| NCT03292952 | KP415 Classroom Study in Children (6-12 Years of Age) With ADHD | Phase3 | ADHD | Completed | 2017-12-20 | 2018-05-16 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | COMPLETED | NCT05668754 |
| Serdexmethylphenidate | Other | Phase PHASE2 | Idiopathic Hypersomnia | COMPLETED | NCT05668754 |
| Sodium phenylbutyrate | Other | Phase PHASE1 | Combined D,L-2-hydroxyglutaric Aciduria | ENROLLING_BY_INVITATION | NCT07125066 |
| Sodium phenylbutyrate | Other | Phase PHASE2 | Medium-chain Acyl-CoA Dehydrogenase Deficiency | RECRUITING | NCT06773026 |
| KP415 oral capsule | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03460652 |
| Placebo oral capsule | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03292952 |
| KP415 oral capsule | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03292952 |
| Placebo | Other | Phase PHASE2 | Idiopathic Hypersomnia | COMPLETED | NCT05668754 |
| Serdexmethylphenidate | Other | Phase PHASE2 | Idiopathic Hypersomnia | COMPLETED | NCT05668754 |
| Sodium phenylbutyrate | Other | Phase PHASE2 | Medium-chain Acyl-CoA Dehydrogenase Deficiency | RECRUITING | NCT06773026 |
| Sodium phenylbutyrate | Other | Phase PHASE1 | Combined D,L-2-hydroxyglutaric Aciduria | ENROLLING_BY_INVITATION | NCT07125066 |